Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital

The HemoScreen hematology point-of-care device is suitable for rapid evaluation of acute leukemia patients

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Performance of the Sysmex White Precursor Channel to discover circulating leukemic blast cells

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translation

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Patient ambassador support in newly diagnosed patients with acute leukemia during treatment: a feasibility study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Comparison of 16 Serological SARS-CoV-2 Immunoassays in 16 Clinical Laboratories

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Hematological patients, receiving intensive chemotherapy (predominantly acute leukemia patients), have repeated postchemotherapy periods with severe bone marrow suppression. As a result, these patients require regular monitoring of the complete blood counts (CBC) for optimal patient care. To reduce the strain on the patient, there is a need for a point-of-care (POC) hematology device that provides rapid and reliable results both in general and in cytopenic samples and is suitable for outpatient clinics. We evaluated the HemoScreen device for the most used CBC parameter both overall and at the lower range.

METHODS: The HemoScreen was compared with the Sysmex XN-9000 in 206 routine venous samples and 79 capillary bedside samples focusing on white blood cells (WBC), absolute neutrophil count (ANC), red blood cells (RBC), PLT and HGB.

RESULTS: The HemoScreen was less precise compared to the acceptance criteria set for larger and more advanced hematology instrument with a CV% 3.0-3.7 for WBCs, 3.6-8.4 for ANCs, 1.1-1.5 for RBCs, 2.5-4.4 for PLTs, and 1.7-2.3 for HGB. Correlation coefficient for all five parameters for the entire range was r >.95 and r >.90 at lower range for venous and capillary samples. Bias limits were within the CTCAE acceptance limits.

CONCLUSIONS: The HemoScreen provides rapid and accurate test results, for evaluation of WBC, PLT, and HGB, as well as at low concentrations for guiding transfusions and postchemotherapy treatment. The device is easy to operate and can measure both venous and capillary samples. Therefore, the HemoScreen is well suited for smaller outpatient clinics and potentially home use.

Original languageEnglish
JournalInternational Journal of Laboratory Hematology (Print Edition)
Issue number1
Pages (from-to)52-60
Number of pages9
Publication statusPublished - Feb 2021

    Research areas

  • acute leukemia patients, complete blood count, hemoglobin, neutropenia, point-of-care, thrombocytopenia

ID: 60806089